GE9:F:F-Genmab A/S (EUR)

COMMON STOCK | |

Last Closing

USD 238.3

Change

-5.60 (-2.30)%

Market Cap

USD 15.01B

Volume

2.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-25 )

Largest Industry Peers for

Symbol Name Price(Change) Market Cap
NNND:F Tencent Holdings Ltd

+3.70 (+7.85%)

USD 428.32B
MATA:F Panasonic Corporation

+0.01 (+5.88%)

USD 20.38B
1CK:F CK Asset Holdings Limited

+0.02 (+0.44%)

USD 13.58B
0PY:F Paycom Soft

-5.35 (-3.52%)

USD 8.85B
2U4:F HICL Infrastructure PLC

-0.01 (-0.65%)

USD 2.89B
28MA:F CIELO SA SPONS. ADR 1

N/A

USD 2.57B
0LA:F ASSETMARK FIN. DL-001

N/A

USD 2.38B
CLN:F The City of London Investment ..

+0.01 (+0.19%)

USD 2.04B
JR0:F Just Group plc

N/A

USD 1.77B
R7I:F RENEWABLES INFRASTRUCTURE

N/A

USD 1.72B

ETFs Containing GE9:F

N/A

Market Performance

  Market Performance vs. Industry/Classification () Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -17.08% N/A N/A 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -17.08% N/A N/A 22% F
Trailing 12 Months  
Capital Gain -30.71% N/A N/A 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -30.71% N/A N/A 20% F
Trailing 5 Years  
Capital Gain 53.44% N/A N/A 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 53.44% N/A N/A 58% F
Average Annual (5 Year Horizon)  
Capital Gain 14.43% N/A N/A 80% B-
Dividend Return 14.43% N/A N/A 74% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 31.92% N/A N/A 37% F
Risk Adjusted Return 45.21% N/A N/A 69% C-
Market Capitalization 15.01B N/A N/A 90% A-

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike